- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Jon Campbell Discusses the Need for More Creative Methods of Value Assessment
Jonathan Campbell, PhD, associate professor, Department of Clinical Pharmacy, Pharmaceutical Outcomes Research, Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of Colorado, discusses the need for more creative methods for value assessment, as well as how one-time, high-cost therapies make it harder to determine value.
Jonathan Campbell, PhD, associate professor, Department of Clinical Pharmacy, Pharmaceutical Outcomes Research, Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of Colorado, discusses the need for more creative methods for value assessment, as well as how one-time, high-cost therapies make it harder to determine value.
Transcript
With more innovative and high-cost therapies entering the market, is there a need for more creative methods for value assessment?
With novel therapies comes great new opportunities for patients. We have the opportunity to cure cancer for patients that didn’t have that opportunity otherwise. With the novel therapies also comes uncertainty in evidence and alongside that we have a very heterogeneous health system in the US. Novel value assessment allows more flexibility in such a health system and gives a structure to novel aspects to potentially curable therapies.
Are one-time, high-cost therapies like gene therapy, which have limited evidence of long-term value, making it harder to determine value?
Probably yes. Traditional value, being cost-effectiveness, one-time therapies don’t really have a challenge in terms of the cost because those are pretty known up front, but the long-term health outcomes are very uncertain. So, MCDA [multi-criteria decision analysis] can help by incentivizing evidence generation in domains such as caregiver burden and insurance value to aid in a more comprehensive understanding of value.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
